Gapping upIn reaction to strong earnings/guidance:
- INGN +14.6%, SQNS +12.3%, CECE +12%, WLH +10.9%, CCRN +10.1%, BLMN +9.8%, STKL +8.9%, PAYS +8.4%, FIVN +8.2%, MRSN +8.1%, CYBR +7.7%, KTOS +6.6%, DVA +6.3%, EVH +6.3%, EVRI +5.9%, HCR +5.6%, HZNP +5.5%, AVLR +5.4%, ICHR +5%, CVIA +4.8%, AES +4.7%, COTY +4.3%, DVN +3.5%, ENBL +3.5%, WEN +3.4%, PODD +3.3%, SSRM +3.2%, PZZA +3.2%, LC +3.1%, PERI +3.1%, IONS +3.1%, TSLX +2.8%, HUM +2.8%, ADAP +2.7%, ODP +2.7%, TGLS +2.7%, ACHV +2.5%, CVS +2.5%, SCOR +2.4%, JAZZ +2.2%, GPRE +2.1%, GOLD +2%, CNR +1.9%, CRCM +1.6%, MYGN +1.6%, GTES +1.3%, PTLA +1.3%, GLMD +1.1%, BCRX +1%
M&A news:
- AYR +16.1% (to be acquired by a newly-formed entity controlled by affiliates of Marubeni Corporation for $32.00/share in cash)
Other news:
- SESN +17.3% (reached agreement with the FDA that the post-marketing confirmatory trial for Vicinium will enroll BCG-refractory patients who have received less-than-adequate BCG)
- WBA +1.5% (after closing 2.6% higher on the day on PE speculation)
- ABR +1.3% (commences $215 mln private placement of Convertible Senior Notes due 2022)
Analyst comments:
- BPMC +3.5% (upgraded to Strong Buy from Outperform at Raymond James)
- LOW +1.2% (upgraded to Outperform from Neutral at Credit Suisse)
- LULU +1.1% (initiated with Strong Buy at Raymond James)
- NKE +0.6% (initiated with Outperform at Raymond James)